BIGBEAR
PHARMACEUTICALS
Lenalidomide is an immunomodulatory agent and a thalidomide analogue with anti-angiogenic and anti-tumor properties.
AuthenticGuaranteeFast DeliveryPrivacy Regulatory Expansion into Frontline TherapyOn February 18, 2015, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has ex···【Read More】
Update: 19 Mar,2026Source: Haiou HealthViews: 73
Regulatory Approval for Advanced Mantle Cell LymphomaOn June 5, 2013, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) a···【Read More】
Update: 19 Mar,2026Source: Haiou HealthViews: 72
Expanded Indication for Darzalex in Relapsed or Refractory Multiple MyelomaOn November 21, 2016, Janssen Biotech, Inc. announced that the U.S. Food an···【Read More】
Update: 19 Mar,2026Source: Haiou HealthViews: 73
Strategic Expansion of Revlimid Maintenance TherapyOn February 22, 2017, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA···【Read More】
Update: 19 Mar,2026Source: Haiou HealthViews: 72
Overview of EltrombopagEltrombopag is an oral non-peptide thrombopoietin receptor agonist (TPO-RA). It increases platelet production by activating the···【Read More】
Update: 19 Mar,2026Source: Haiou HealthViews: 73
Regulatory Milestone and Expanded Treatment IndicationOn June 27, 2019, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that t···【Read More】
Update: 19 Mar,2026Source: Haiou HealthViews: 71
Regulatory Milestone for Pfizer’s Oncology PortfolioOn February 12, 2025, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration···【Read More】
Update: 19 Mar,2026Source: Haiou HealthViews: 74
Copyright2024@ BIGBEAR All right reserved BIGBEAR
